PBK/TOPK表达与老年急性髓系白血病患者治疗反应和生存预后的关联分析

doi:10.3969/j.issn.1673-8640.2022.011.003

摘要/Abstract

摘要：

目的评估PBK/TOPK表达水平与老年急性髓系白血病（AML）患者治疗反应和生存预后的关系。方法选取2016年7月-2017年3月衢州市人民医院80例AML患者（AML组），以32例行骨髓活检的老年非恶性血液疾病患者为对照组。收集AML组一般临床资料和细胞遗传学、分子生物学相关检测结果。采用实时荧光定量聚合酶链反应（RT-qPCR）检测所有患者骨髓单个核细胞PBK/TOPK的相对表达量。对AML组进行诱导治疗，并统计完全缓解（CR）率。对AML患者进行随访，采用Kaplan-Meier生存曲线分析患者PBK/TOPK表达与总生存期（OS）和无进展生存期（EFS）的关系。结果 RT-qPCR结果显示，AML组骨髓单个核细胞PBK/TOPK表达高于对照组，PBK/TOPK表达与患者血红蛋白（Hb）、血小板（PLT）计数、染色体核型和基因突变类型有关，且PBK/TOPK高表达患者CR率较低（P<0.05）。PBK/TOPK低表达患者3年生存率高于PBK/TOPK高表达患者（P<0.05），PBK/TOPK高表达患者术后3年EFS短于低表达患者（P<0.05）。结论 PBK/TOPK在老年AML患者中表达升高，并且其高表达与患者临床特征有关，对评估老年AML患者生存预后具有一定的意义。

关键词: PBK/TOPK, 急性髓系白血病, 老年人群, 治疗反应, 生存期

Abstract:

Objective To evaluate the relationship of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia（AML）. Methods From July 2016 to March 2017，80 elderly patients with AML in Quzhou People’s Hospital were enrolled，and 32 patients with non malignant blood diseases undergoing bone marrow biopsy were enrolled as control group. The general clinical data，cytogenetic and molecular biological data of AML group were collected. The relative expression of PBK/TOPK in bone marrow mononuclear cells was determined by real-time fluorescence quantitative polymerase chain reaction（RT-qPCR）. The AML group was treated with induction therapy，and the complete remission（CR） rate was calculated. The patients were followed up for 3 years. The survival curve was drawn by Kaplan-Meier method. The relationship between PBK/TOPK expression level and overall survival（OS） and event free survival（EFS） was analyzed. Results The results of RT-qPCR showed that the expression of PBK/TOPK in bone marrow mononuclear cells of elderly patients with AML was higher than that of control group. The expression level of PBK/TOPK was related to hemoglobin（Hb），platelet（PLT）count，chromosome karyotype and gene mutation. The high expression of PBK/TOPK had low CR rate（P<0.05）. The results of survival analysis showed that the 3-year survival rate of PBK/TOPK low expression group was higher than that of PBK/TOPK high expression group（P<0.05），and the EFS of patients with high PBK/TOPK expression was lower than that of patients with PBK/TOPK low expression（P<0.05）. Conclusions The expression of PBK/TOPK in elderly patients with AML is higher，and its high expression is related to the clinical characteristics of patients，which has a predictive value for the survival and prognosis of elderly patients with AML.

Key words: PBK/TOPK, Acute myeloid leukemia, Elder population, Treatment response, Survival time

中图分类号:

R393

吴文萍, 徐林娟, 王佳亨, 张娜娜. PBK/TOPK表达与老年急性髓系白血病患者治疗反应和生存预后的关联分析[J]. 检验医学, 2022, 37(11): 1017-1022.

WU Wenping, XU Linjuan, WANG Jiaheng, ZHANG Nana. Correlation analysis of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia[J]. Laboratory Medicine, 2022, 37(11): 1017-1022.

图/表 5

表1 80例老年AML患者一般临床资料

图1 AML组和对照组骨髓单个核细胞PBK/TOPK的表达

表2 BK/TOPK表达与老年AML患者临床特征的关系例

表3 不同PBK/TOPK表达水平老年AML患者CR率例（%）

组别	例数	CR	非CR
PBK/TOPK高表达组	49	15（30.61）	34（69.39）
PBK/TOPK低表达组	31	21（67.74）	10（32.26）

图2 BK/TOPK表达与老年AML患者OS、EFS的关系注：（a）老年AML患者总生存率；（b）老年AML患者无复发生存率； PBK/TOPK高表达组； PBK/TOPK低表达组。

参考文献 21

[1]	王霞, 张斌. 混合表型急性白血病患者骨髓细胞形态学与流式免疫表型特点[J]. 检验医学, 2019, 34(3):235-239.
[2]	张校辉, 邢江涛, 张玉娜, 等. 变异性急性早幼粒细胞白血病实验室检查结果分析[J]. 检验医学, 2019, 34(10):871-875.
[3]	ABRAHÃO R, HUYNH J C, BENJAMIN D J, et al. Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults:a population-based study[J]. Int J Epidemiol, 2021, 50(2):663-674. DOI URL
[4]	齐瑶, 赵明峰, 肖霞, 等. 地西他滨联合减量FLAG方案治疗老年高危急性髓系白血病患者的临床疗效观察[J]. 中国实验血液学杂志, 2020, 28(5):1440-1444.
[5]	董杨, 邓来军, 展昭民, 等. 地西他滨联合小剂量米托蒽醌预激方案治疗老年急性髓系白血病的疗效及安全性研究[J]. 中国实用内科杂志, 2020, 40(7):567-570.
[6]	张伟. PBK/TOPK在宫颈癌组织中的表达及临床意义[J]. 中国免疫学杂志, 2015, 31(12):1688-1691.
[7]	贾建民, 葛永超, 段堃, 等. PBK/TOPK表达对膀胱癌BIU-87细胞株增殖及迁移的影响[J]. 国际泌尿系统杂志, 2020, 40(1):5-8.
[8]	李晓勇, 刘涛, 李建, 等. PBK/TOPK在乳腺癌细胞中介导MEK非依赖性ERK激活中作用机制分析[J]. 中国细胞生物学学报, 2020, 42(1):55-61.
[9]	VARDIMAN J W, HARRIS N L, BRUNNING R D. The World Health Organization(WHO)classification of the myeloid neoplasms[J]. Blood, 2002, 100(7):2292-2302. DOI URL
[10]	张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007.
[11]	BELL J A, GALAZNIK A, HUELIN R, et al. Effectiveness and safety of therapeutic regimens for elderly patients with acute myeloid leukemia:asystematic literature review[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(7):e303-e314. DOI URL
[12]	EFFICACE F, BRECCIA M, AVVISATI G, et al. Health-related quality of life,symptom burden,and comorbidity in long-term survivors of acute promyelocytic leukemia[J]. Leukemia, 2019, 33(7):1598-1607. DOI URL
[13]	CHEBIHI Z T, BELKHAYAT A, CHADLI E, et al. Cytogenetic profile of moroccan pediatric acute lymphoblastic leukemia:analysis of 155 cases with a review of the literature[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(6):e241-e248. DOI URL
[14]	徐敏, 吴晓. 老年急性髓系白血病诱导治疗疗效与预后分析[J]. 中国临床研究, 2019, 32(3):367-370.
[15]	SCHNEIDER F, HOSTER E, SCHNEIDER S, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML(NK-AML)[J]. Ann Hematol, 2012, 91(1):9-18. DOI URL
[16]	LIU Y, LIU H, CAO H, et al. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis[J]. Oncol Rep, 2015, 34(6):3288-3296. DOI URL
[17]	ALACHKAR H, MUTONGA M, MALNASSY G, et al. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia[J]. Oncotarget, 2015, 6(32):33410-33425. DOI PMID
[18]	SIMONS-EVELYN M, BAILEY-DELL K, TORETSKY J A, et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells[J]. Blood Cells Mol Dis, 2001, 27(5):825-829. DOI URL
[19]	田鑫, 贺湘玲, 袁小叶, 等. TOPK/PBK在儿童恶性淋巴瘤与淋巴结反应性增生的淋巴结组织表达的研究[J]. 中国当代儿科杂志, 2018, 20(3):214-217.
[20]	陈渠发, 陈毅斌, 张锡迎, 等. PBK/TOPK在HCC组织中的表达与HCC对奥沙利铂敏感性的关系研究[J]. 解放军预防医学杂志, 2019, 37(3):35-37.
[21]	盛俊杰, 万岁桂. 红系增生髓系肿瘤的诊断分类演变[J]. 白血病·淋巴瘤, 2019, 28(2):125-128.